Latest Regulatory Progress News

Finder Energy is pushing ahead with its Kuda Tasi and Jahal (KTJ) oil development, lodging key regulatory approvals and progressing debt financing amid a firmer Brent oil price outlook. The company targets final investment decision by mid-2026 and aims for first oil in late 2027 or early 2028.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.

Aguia Resources has received official commercialisation approval for its Pampafos phosphate fertiliser project, enabling invoicing and marketing ahead of a targeted sales campaign designed to boost cash flow by mid-2026.

Greatland Resources has clinched both state and federal environmental approvals for its Havieron gold-copper project, paving the way for a Final Investment Decision targeted in June 2026 and advancing construction activities.

Native Mineral Resources (ASX:NMR) recorded its strongest monthly processing since recommissioning in April 2026, with 24,101 dry tonnes milled and a 20% rise in gold recovered. The transition to higher-grade feed from Blackjack Mid Pit and Podosky is set to underpin production gains through FY2027.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

PMET Resources has secured crucial non-binding letters of support from Export Development Canada and Germany’s KfW IPEX-Bank, marking a key step toward financing its Shaakichiuwaanaan critical minerals project in Quebec ahead of an updated feasibility study.

Alterity Therapeutics has showcased compelling Phase 2 data for ATH434 in Multiple System Atrophy, paving the way for a Phase 3 trial with FDA engagement targeted for mid-2026.

EBR Systems has landed a significant purchasing agreement with Advocate Health, the third-largest US non-profit health system, opening access for its WiSE wireless cardiac pacing technology across 69 hospitals in eight states.